Table of Contents
- Trial overview
- Who is being studied
- Treatments and comparators
- Phase and study design
- Endpoints being measured
- What the study may mean for patients
Trial overview
The main study in the data is titled FORAGER-2 and is listed as an authorised Phase 3 interventional trial.[1] It is studying people with cancer in the urinary tract, including bladder cancer that is advanced or has spread.[1]
The trial includes “(S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE” as part of the study treatment plan.[1] The study purpose is to see whether the treatment is safe and whether it can help people with this cancer.[1]
Who is being studied
The trial targets participants with carcinoma, transitional cell, urinary bladder neoplasms, and neoplasm metastasis.[1] In simple terms, this means the study is focused on cancer that starts in the lining of the urinary tract and may have spread to other parts of the body.[1]
The brief summary says the study is for people with bladder cancer that is advanced or has spread.[1] This is important because the trial is not looking at early cancer only; it is focused on more serious disease.[1]
Treatments and comparators
The study compares vepugratinib with placebo.[1] A placebo is a look-alike treatment used for comparison, so researchers can see whether the study medicine makes a difference.[1]
The data also shows that vepugratinib or placebo is given together with enfortumab vedotin and pembrolizumab.[1] The trial therefore studies a combination approach rather than a single medicine alone.[1]
The intervention list includes oral use for LOXO-435 and the listed substance, and intravenous use for pembrolizumab and enfortumab vedotin.[1] The source data does not provide more detail about dosing beyond what is listed in the intervention names.[1]
Phase and study design
This is an interventional study, which means the researchers are assigning treatments and then measuring what happens.[1] The study is in Phase 3, a later stage of clinical research that usually involves larger groups and direct comparison of treatments.[1]
The enrollment is listed as 503 participants.[1] The brief summary also says participation could last up to about 6 years, showing that the study includes long-term follow-up.[1]
Endpoints being measured
The main outcomes include safety and tolerability of vepugratinib in combination with enfortumab vedotin and pembrolizumab.[1] Safety and tolerability mean how safe the treatment appears and how well people can handle it during the study.[1]
Another key outcome is overall response rate (ORR).[1] This measures how many participants have their cancer shrink or disappear during treatment.[1]
The study also measures progression-free survival (PFS) by blinded independent central review (BICR).[1] PFS means the time before the cancer gets worse, and BICR means scan results are reviewed by experts who do not know which treatment the person received.[1]
What the study may mean for patients
This trial is designed to learn whether the study treatment can help people with advanced urinary tract cancer while keeping safety under close review.[1] Because it is a Phase 3 study, the results may help show whether the treatment has enough benefit to support future use in this cancer setting.[1]
For patients, the most important parts of the study are the cancer type being targeted, the comparison against placebo, and the long follow-up period.[1] These details show that the researchers are looking not only at short-term tumor response, but also at how the treatment performs over time.[1]
